Elekta B

Elekta increased adjusted gross margin to 42.6% and adjusted EBIT margin to 11.2% thanks to cost cuts, a better product mix and tariff refunds, while net revenue fell 2% on a currency-adjusted basis. Order intake grew 3% with a book-to-bill ratio of 1.11, so the company left its full-year guidance unchanged. Investors focused on the weaker revenue growth, sending the stock down about 5.6% in pre-market trading. Management views the margin improvement as a success of the restructuring but stresses the need to align growth with the market. » Más en de.investing.com

Elekta published mixed results for Q4 2025/26: currency-adjusted net sales down 1%, adjusted EBIT margin 18.9% and gross margin 39.9%. Reported EBIT was negative at -461 million SEK after significant one-off charges, which dented market confidence. Investors reacted with a roughly 14% pre-market share price drop, with weakness in the Asia-Pacific region and the Middle East and currency effects cited as main reasons. Management said the one-off charges were non-cash and pointed to operational improvements and upcoming details at the Capital Markets Day. » Más en de.investing.com

Elekta A B will release figures for the quarter ending 30 April 2026 on 28 May 2026. Ten analysts forecast earnings per share of 1.40 SEK after a loss of -1.010 SEK in the year‑ago quarter. Eleven analysts expect revenue of around 5.01 billion SEK, a decline of 2.74% from 5.16 billion SEK a year earlier. For the fiscal year, average analyst estimates are 3.28 SEK earnings per share and 16.93 billion SEK in revenue versus 0.620 SEK and 18.02 billion SEK in the prior year. » Más en finanzen.net

Elekta reports solid operational progress for Q3 2025/26, but this was offset by a negative currency effect of 548 million SEK and restructuring charges of 417 million SEK. Reported revenue fell 9.7% to 4,239 million SEK, while constant‑currency revenue growth was +2%. Adjusted gross margin and EBIT margin improved slightly, cash flow and net debt improved, and the company expects annual cost savings of more than 500 million SEK. Elekta also received FDA approval for the Elekta‑Evo system and confirmed its full‑year outlook despite continued currency pressure. » Más en de.investing.com

S&P Global Ratings has revised its outlook for Elekta AB from 'stable' to 'negative' because of persistently high debt and weaker-than-expected cash flow, while affirming the company's credit rating. The adjusted debt ratio exceeded forecasts in fiscal year 2025, and both EBITDA and margin fell short of expectations. S&P anticipates only a slow recovery in profitability over the coming years and sees a risk of further downgrades if the debt situation does not improve. » Más en de.investing.com